((自动化翻译由路透提供，请见免责声明 ))
* CNS Pharmaceuticals Inc 预计将于 11 月 13 日公布截至 0001 年 1 月 1 日的业绩(预计)
*
* LSEG分析师对CNS Pharmaceuticals Inc的平均预期是每股亏损10美分。
* 分析师对该公司股票的评级为 "买入"。
* 生物技术与医学研究同行的平均一致建议也是 "买入"。
* 华尔街对 CNS Pharmaceuticals Inc 的 12 个月目标价中位数为 0.50 美元，高于其 0.12 美元的最新收盘价。
11月11日 - 本摘要于北京时间 11 月 11 日 15:31 机器生成。 除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。如有任何其他问题或反馈，请联系 RefinitivNewsSupport@thomsonreuters.com。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.